-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Neutral on Windtree Therapeutics, Maintains $7 Price Target

Benzinga·12/04/2024 11:34:25
Listen to the news
HC Wainwright & Co. analyst Vernon Bernardino reiterates Windtree Therapeutics (NASDAQ:WINT) with a Neutral and maintains $7 price target.